 | | Vol. 5.42 – 12 November, 2021 |
| |
|
|
| Scientists generated functional human pluripotent stem cell-derived cholangiocytes that displayed many characteristics of mature bile duct cells including high levels of cystic fibrosis transmembrane conductance regulator and the presence of primary cilia capable of sensing flow.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers revealed that delivery of miR-122 was associated with downregulation of key genes in involved in metastatic and cancer inflammation pathways, including several pro-inflammatory factors, matrix metalloproteinases, and other extracellular matrix degradation enzymes.
[Cancer Research] |
|
|
|
| High-throughput RNA-seq was used to identify the differentially expressed circRNAs upon IL-6 stimulation in intrahepatic cholangiocarcinoma cells.
[Cancer Research] |
|
|
|
| The authors showed that Myc-driven hepatocellular carcinoma was dramatically aggravated in mice with hepatocyte-specific Ptpn11/Shp2 deletion.
[Cell Reports] |
|
|
|
| Investigators contracted an immune-related lncRNA signature for prospective assessment to predict early recurrence of hepatocellular carcinoma (HCC) that had important clinical implications for improving predictive outcomes and guiding individualized treatment in HCC patients.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Researchers demonstrated that Linc-ROR played an oncogenic role in hepatocellular carcinoma in part through its positive regulation of DEPDC1 expression.
[Cell Death & Disease] |
|
|
|
| The authors showed that somatic copy number alteration of mitoribosomal protein genes was a key mechanism of bioenergetic deregulation in hepatocellular carcinoma.
[Cell Death & Disease] |
|
|
|
| Scientists showed that FATP5 was downregulated in hepatocellular carcinoma tissues and even much lower in vascular tumor thrombi.
[Oncogenesis] |
|
|
|
| Researchers used a tripartite model of human hepatocellular carcinoma cell line and mesenchymal stromal cells co-cultured with peripheral blood mononuclear cells to investigate the impact of tumor and stromal cell interactions on the development of immunosuppressive tumor microenvironment.
[Frontiers in Cell and Developmental Biology] |
|
|
|
| Investigators introduced NTCP-S267F variant and tested the infectivity by hepatitis B virus in genetically edited hepatic cells.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Inhibition of matrix metalloprotease 2 (MMP2) restricted functional transfer of hepatic miRNAs across the hepatic and non-hepatic cell boundaries and by targeting MMP2, scientists could reduce the innate immune response in the mammalian liver by preventing intra-tissue miR-122 transfer.
[iScience] |
|
|
|
| The authors found that the expression of CD5 molecule like (CD5L) was increased in the livers of mice after acetaminophen (APAP) overdose, revealing that CD5L may be a potential therapeutic target for prevention and treatment of APAP-induced liver injury.
[Cell Death Discovery] |
|
|
|
| Investigators found that miR-571 inhibited the apoptosis of human hepatic stellate cells and promoted cell proliferation and migration. Its up regulation promoted the expression of Notch3 and Jagged1, and promoted the expression of related fibroblasts.
[Scientific Reports] |
|
|
|
|
| The authors provide information on the immune microenvironments underlying the response or resistance of hepatocellular carcinoma to immunotherapies.
[Nature Reviews Clinical Oncology] |
|
|
|
| Scientists discussed current concepts related to the role of immune cells in the onset and progression of non-alcoholic steatohepatitis.
[Nature Reviews Immunology] |
|
|
|
| Investigators review the updates in epidemiology and molecular mechanism of high-salt diet (HSD)-induced non-alcoholic fatty liver disease and provide a novel insight into the role of HSD in the regulation of lipid metabolism.
[European Journal of Clinical Investigation] |
|
|
|
|
| TransThera Sciences, Inc. announced that the US FDA has granted Fast Track Designation to its Phase II stage product TT-00420 for the treatment of patients with cholangiocarcinoma who have no standard treatment options.
[TransThera Sciences] |
|
|
|
|
| November 19 – December 2, 2021
Virtual |
|
|
|
|
|
| | German Research Center for Environmental Health – Oberschleißheim, Germany |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | King’s College London – London, England, United Kingdom |
|
|
|
| | Saint Louis University – St. Louis, Missouri, United States |
|
|
|
| | Genome Institute of Singapore – Singapore, Singapore |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
